#USA #New York #Pomerantz LLP #Investor Alert #NeoGenomics

Pomerantz Law Firm Investigates NeoGenomics Investments

On August 11, 2025, the Pomerantz Law Firm announced an investigation regarding claims from investors of NeoGenomics, Inc. (NASDAQ: NEO). This investigation revolves around potential securities fraud and other unlawful business practices allegedly committed by NeoGenomics and several of its executives.

Financial Disappointments Prompt Scrutiny

NeoGenomics generated significant attention recently after releasing its financial results for the second quarter of 2025. The report revealed that the company earned revenues totaling approximately $181.3 million, a figure that fell short of market consensus estimates. Additionally, NeoGenomics reported a staggering net loss of $45.1 million, which raises various red flags for investors and stakeholders alike.

In an unexpected turn, NeoGenomics also revised its revenue forecast for 2025, adjusting it downward from an estimated $753 million to a more modest range of $720 million to $726 million. The revised forecast did not end there; an outlook for adjusted EBITDA was also lowered significantly—from a range of $55 million to $58 million down to $41 million to $44 million.

Following this grim financial disclosure, NeoGenomics’ stock plummeted by $1.21 per share, equating to a drastic 18.73% drop, closing at $5.25 on the same day. This sharp decrease prompted concerns among investors, many of whom are now seeking legal recourse to understand their rights better and determine if they have been wronged.

Pomerantz LLP: A Leader in Securities Class Action

With a reputation as one of the premier firms in corporate, securities, and antitrust class litigation, Pomerantz LLP is not new to navigating complex legal waters. Established over 85 years ago by the late Abraham L. Pomerantz—often referred to as the